Evidence map›Paper›PMID 42486949›Full record

ArticleNature chemistry2026

A versatile strategy for oligonucleotide functionalization via on-support phosphitylation.

Ayan Dasgupta, Sebastian Golojuch, Li Xiao, Nour Eddine Fahmi, Edward A Anderson, Tom Brown

Abstract read
In one paragraph

Article in Nature chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Ayan DasguptaChemistry Research Laboratory, Department of Chemistry, University of Oxford, Oxford, UK.ORCID http://orcid.org/0000-0001-9945-8334
Sebastian GolojuchChemistry Research Laboratory, Department of Chemistry, University of Oxford, Oxford, UK.ORCID http://orcid.org/0000-0003-1117-3401
Li XiaoEli Lilly and Company, Lilly Corporate Center, Indianapolis, IN, USA.ORCID http://orcid.org/0000-0003-0248-7871
Nour Eddine FahmiEli Lilly and Company, Lilly Corporate Center, Indianapolis, IN, USA. fahmi_nour_eddine@lilly.com.
Edward A AndersonChemistry Research Laboratory, Department of Chemistry, University of Oxford, Oxford, UK. edward.anderson@chem.ox.ac.uk.ORCID http://orcid.org/0000-0002-4149-0494
Tom BrownChemistry Research Laboratory, Department of Chemistry, University of Oxford, Oxford, UK. tom.brown@chem.ox.ac.uk.ORCID http://orcid.org/0000-0002-6538-3036

Funding

Eli Lilly and Company (Lilly) LRAP 24RCUK | Engineering and Physical Sciences Research Council (EPSRC) EP/Z536143/1
6 · The paper itself

Abstract

Chemically modified nucleic acids such as antisense oligonucleotides, small interfering RNA and CRISPR guide RNA have emerged as transformative modalities in modern medicine, providing new strategies for the treatment of genetic and metabolic disorders, viral infections and cancer. However, their application is limited by challenges related to intracellular delivery and targeting, advances in which would benefit from a broader range of methods for chemical functionalization. Here we describe a streamlined approach using inexpensive, bench-stable alcohols or nucleosides that enables site-selective modification at the 5' and 3' termini and at internal sites of synthetic oligonucleotides. Our strategy offers a conceptually straightforward solution to this problem through the in situ generation of phosphoramidites on the solid-supported oligonucleotide. The methodology displays high coupling efficiency, high functional-group compatibility with azides, amines and thiols, and efficient recovery of excess alcohols/monomers, thus offering a robust platform for advancing and diversifying therapeutic oligonucleotide modification.

Indexed as

OligonucleotidesOrganophosphorus CompoundsAlcoholsAminesAlcoholsAminesOligonucleotidesOrganophosphorus Compoundsphosphoramidite

Identifiers

PMID42486949
PMCPMC13623645

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.